MONOCLONAL ANTIBODY DEVELOPMENT AND PRODUCTION:
TECHNOLOGICAL PRINCIPLES
Antonio Moreira University of Maryland Baltimore County
IV SYMPOSIUM SINDUSFARMA-IPS/FIP-ANVISA New frontiers in manufacturing
technology, regulatory sciences and pharmaceutical quality system
Brasilia June 22, 2015
Presentation Outline
• Characteristics of monoclonal antibody molecules • Production technologies • Quality control • Recent advances • Conclusions
2
Biopharmaceuticals on the Market – Examples
• Interferons (Intron A, Pegintron, Betaseron, Avonex) • Interleukins (IL2, IL11) • Fusion Proteins (Enbrel, Orencia) • Bexxar (Fully Murine) • Remicade, Rituxan, Reopro, Simulect, Erbitux (chimeric) • Herceptin, Avastin, Tysabri, Synagis, Zenapax (humanized) • Humira (Fully human) • Biosimilars (Remsima by Celltrion and Inflectra by Hospira) • Antibody-Drug Conjugates
− Adcertis by Takeda − Kadcyla by Genentech
3
Coordinates from “Anatomy of the Antibody Molecule” by E. Padlan, Mol.Immunol., 31, 169, 1994. PDB file “21g2”; Picture made using RasMol: R. Sayle, E.J. Milner-White, TIBS, 20, 374, 1995
A Representative Antibody Molecule
S-S
S-SS-S
S-S
Carbohydrate
VH
VL
CL
CH1
CH2
CH3
Intrachain disulfide bonds
Hinge region
L Chain hypervariable regions
H Chain hypervariable regions
5
Current and future issues in the manufacturing and development of monoclonal antibodies. S. Kozlowski and P. Swann. Advanced Drug Delivery Reviews 28 (2006), 707-72, 707-722.
6
Complex Carbohydrate in Antibody Structure
7
BioPharm International, February 2013
Figure 2: List of FDA-approved antibody therapeutics.
8
Thayer, C&EN Houston. cen.acs.org. October 7, 2013.
KEY TARGETS Developers are trying to create functional replicas of leading biologic drugs.SOURCES: Company data, Biotechnology Information Institute
9
Herceptin Binding to HER2 Receptor
10
Perjeta ® Mechanism of Action Step #4 PERJETA + Herceptin provide a more comprehensive blockade of HER2-driven signaling pathways.
11
Avastin® ( Bevacizumab)
• Tumors release the VEGF protein causing nearby cells to sprout new vessels by angiogenesis. – New blood cells feed the tumor
• Bevacizumab is an angiogenesis inhibitor – Mechanism of action is by inhibiting vascular endothelial growth
factor ( VEGF) – Initially approved for colon cancer in 2004 – Has been approved for us in other cancers such as: lung, renal,
ovarian, glioblastoma
12
13
Trends in Upstream and Downstream Process Development for Antibody Manufacturing. P. Gronemeyer, R. Ditz and J. Strube. Bioengineering, 2014, 1, 188-212; doi: 10.3390/bioengineering1040188.
14
Recent advances in large-scale production of monoclonal antibodies and related proteins. A. A. Shukla and J. Thömmes. Trends in Biotechnology, Vol. 28, No. 5, 253-261. March 2010.
15
Bioreactor Operating Modes
• Batch • Fed-Batch • Continuous • Perfusion
16
Table 1: Selected Perfusion Operations Issues: PRODUCT MANUFACTURER
IL-12/23 Mab (Stelara)** Janssen/J&J
TNF Mab (Simponi) Janssen/J&J
Glucosidase alfa (Myozyme)** Genzyme/Sanofi
Galactosidase alfa (Fabrazyme)** Genzyme/Sanofi
Protein C (Xigris) Lonza for Eli Lilly
Factor VIII (Kogenate-FS)** Bayer
Interferon beta (Rebif)** Merck-Serono
IL-2 receptor Mab (Simulect) Novartis
TNF mAb (Remicade)** Janssen/J&J
FSH (Gonal-F) Merck-Serono
Galactosidase. beta (Cerezyme)** Genzyme/Sanofi
Platelet Mab Fab (Reopro) Janssen/J&J **Annual sales over 500 million
Source: 11th Annual Report and Survey on Biomanufacturing Capacity and Production, April 2014
Continuous Bioprocessing and Perfusion. E. Langer. Pharmaceutical Processing, July/August 2014, pg. 13.
17
Selected Continuous Bioprocessing Benefits
• Reduction in facility size, manufacturing footprint, etc. • Significant costs savings, particularly investment in facilities • Increases in flexibility • No scale-up of bioprocesses • Increased process robustness • Less manual interactions • Less bulk fluid input • Less sensor insertions and other incursions into the process • Increased automation • PAT and upfront bioprocess design using QbD can be easier to implement
Continuous Bioprocessing and Perfusion. E. Langer. Pharmaceutical Processing, July/August 2014, pg. 13.
18
Trends in Upstream and Downstream Process Development for Antibody Manufacturing. P. Gronemeyer, R. Ditz and J. Strube. Bioengineering, 2014, 1, 188-212; doi: 10.3390/bioengineering1040188.
19
Recent advances in large-scale production of monoclonal antibodies and related proteins. A. A. Shukla and J. Thömmes. Trends in Biotechnology, Vol. 28, No. 5, 253-261. March 2010.
20
Protein A
• Cell Wall Component of Several Strains of Staphylococcus aureus
• It is a Single Polypeptide Chain with Molecular Weight of 42,000 Daltons
• Specifically Binds to the Fc Region of Immunoglobulin Molecules
• Four High Affinity Binding Sites per Molecule
21
Recent advances in large-scale production of monoclonal antibodies and related proteins. A. A. Shukla and J. Thömmes. Trends in Biotechnology, Vol. 28, No. 5, 253-261. March 2010.
22
Trends in Upstream and Downstream Process Development for Antibody Manufacturing. P. Gronemeyer, R. Ditz and J. Strube. Bioengineering, 2014, 1, 188-212; doi: 10.3390/bioengineering1040188.
23
Current and future issues in the manufacturing and development of monoclonal antibodies. S. Kozlowski and P. Swann. Advanced Drug Delivery Reviews 28 (2006), 707-72, 707-722.
24
Current and future issues in the manufacturing and development of monoclonal antibodies. S. Kozlowski and P. Swann. Advanced Drug Delivery Reviews 28 (2006), 707-72, 707-722.
25
Industrialization of mAb production technology. The bioprocessing industry at a crossroads. B. Kelley. mAbs, (2009) Vol. 1, Issue 5, 443-452
26
Production capacity estimates for mammalian cell-derived mAbsa
Year CMO Product company
Total Capacity at 2 g/L
Capacity at 5 g/L
2007 500 kL 1,800 kL 2,300 kL 70 tons/yr 170 tons/yr 2010 700 kL 2,700 kL 3,400 kL 100 tons/yr 255 tons/yr 2013 1,000 kL 3,000 kL 4,000 kL 120 tons/yr 300 tons/yr
aCapacity estimates from ref. 8.
27
Industrialization of mAb production technology. The bioprocessing industry at a crossroads. B. Kelley. mAbs, (2009) Vol. 1, Issue 5, 443-452
28
Industrialization of mAb production technology. The bioprocessing industry at a crossroads. B. Kelley. mAbs, (2009) Vol. 1, Issue 5, 443-452
29
Industrialization of mAb production technology. The bioprocessing industry at a crossroads. B. Kelley. mAbs, (2009) Vol. 1, Issue 5, 443-452
Quality Control of MAbs – The Challenges
• Large Complex Molecules • Complex Manufacturing Systems • Long Production Times • Raw Material Concerns • Stability of Raw Materials, Cell Lines, Intermediates,
Drug Substance and Drug Product • Changes and Comparability • Immunogenicity • Biosimilar MAbs
30
QC Testing of Monoclonal Antibody Products
• QC Release – Cell Culture Potency Bioassay – Antigen Binding Assay – + ADCC if Mode of Action has Fc effector
function implicated • Characterization of Reference Material and
Comparability
31
CanAg + Tumor Cell
Poly-lysine Alkaline phosphatase
Cell Based ELISA
2° Ab
2° Ab - goat anti-human IgG
Example: QC Certificate of Analysis for a Monoclonal Antibody Drug Substance
Parameter Test Methodology Typical Specification Identity Peptide Map Consistent with Reference Material
(retention time &% area comparison)
Oligosaccharide Profile Consistent with Reference Material (X % G0, G1 etc.)
Purity SDS-PAGE or CGE Consistent with Reference Material (Specify % distribution and ~ MWt.)
Monomer Content by SEC ≥ 95% IND; ≥98% BLA ≤ 1.5% Aggregate; ≤ 0.5% Fragment
IEF Consistent with Reference Material (Specify % distribution and ~ pI)
Residual Host Cell Proteins ≤ 100 ppm (< 0.0001%)* (IND) Ion Exchange Chromatography Consistent with Reference Material
(retention time &% area comparison)
Example: QC Certificate of Analysis for a Monoclonal Antibody Drug Substance
Parameter Test Methodology Typical Specification
Purity (cont.) Residual DNA ≤ 1 ppm *(IND) Residual Protein A ≤ 10 ppm* (IND) Other process related residuals
Depends on analyte measured
Potency Antigen Binding ELISA or SPR
50-150% IND; 75-125% BLA
Cell Culture Bioassay 50-150% IND; 75-125% BLA Compared to Reference Material
Safety Endotoxin <5Eu/mL FDA guidelines Bioburden NMT 1 CFU/mL Sterility
Strength Protein Content by A280 As dictated by process Product Quality pH ± 0.1 pH unit
Color and Appearance Describe solution properties Excipients Quantitative Determination
Types of Changes
• Cell Line / Culture Conditions • Scale / Site • Methods • Purification Scheme • Formulation, Storage, Dosage, Delivery Route and
Systems • Components / Vendors / Suppliers /CMO
35
Frequently Cited Concerns
• Animal Derived Components • Aggregate Levels • Immunogenicity • Single Source • Comparability • Reprocessing and Retesting • Validation Deficiencies • Capacity
36
Antibody Fragmentation
37
Example Antibody Fragments Approved Products
1. LUCENTIS® INN Name: Ranibizumab Drug Substance: IgG1, anti-(hVEGF) Fab fragment (human-
mouse monoclonal rhu Fab V2 Ɣ1-chain), disulfide with human-mouse monoclonal rhu Fab V2 Κ-chain
Manufacturer: Genentech Production Process: E-coli fermentation, homogenization, heat
hold, dilution/pH adjustment (if necessary), centrifugation, filtration, 4 chromatography steps, centrifugation, UF/DF, dilution, buffer adjustment, formulation
Manufacturing changes Cell line, cell culture conditions, Implemented: fermentation process parameters,
purification process, finished product formulation
Example Antibody Fragments Approved Products (cont.)
2. CIMZIA® INN Name: Certolizumab pegol Drug Substance: Recombinant, humanized, Fab' fragment with
specificity for human TNFα conjugated to polyethylene glycol (PEG) via a maleimide group
Manufacturer: Drug substance is manufactured by Sandoz GmbH for UCB
Production Process: E-coli fermentation, primary isolation, purification, PEGylation
Manufacturing changes Site, scale, manufacturing process changes Implemented: (primary recovery, downstream processing)
39
BioPharm International, February 2013
Figure 1: Primary mechanism of action of antibody-drug conjugates: targeted delivery of a potent cytotoxic agent to cause cell death.
40
Micro View of ADC
41
42
Why Make Antibody-Drug Conjugates (ADCs)?
• MAbs have exquisite selectivity and affinity for their target antigens
• They are not always effective as standalone therapies, but are excellent targeting modalities
• MAbs may thus serve as delivery vehicles to selectively deliver agents (toxins, radionuclides, imaging agents) to specific tissues
• Much current interest in delivering cytotoxics to cancer tissue via targeting tumor-selective antigens
43
Challenges in Development of Antibody Drug Conjugates
• Toxic molecule must stay attached to Mab while in circulatory system but be released after introduction into the cell.
• Conjugated Mab must retain the high affinity for the tumor cell antigen.
• The toxin must be released from the Mab, internalized, and then achieve a sufficient intracellular concentration to promote cell death.
• The potency of the released toxin must be high enough to kill tumor cells at low concentrations.
44
Challenges in Development of Antibody Drug Conjugates (cont.)
• Free toxin may be extremely dangerous due to high level of potency
• Difficult to work with in manufacturing and QC operations • Special production facilities may be needed • Design of linker, stability and conjugation scheme may
be difficult to achieve.
45
The MAb - Considerations
• Can access fully human antibodies against desired target antigens with current technology (transgenic animals, phage display)
• May possess cytotoxicity alone (CDC, ADCC) • Target antigens are tumor-selective, not tumor-specific! • Selectivity, affinity
46
The Payload - Considerations
• Toxins utilized in current ADCs are highly cytotoxic – 100x more potent than first generation ADCs
• Delivery must be well-controlled or there will be systemic toxicity – importance of linker design
• Two general classes of toxin: – Inhibitors of microtubule polymerization – Molecules that damage DNA
47
Kadcyla. http://www.rxlist.com/kadcyla-drug.htm
48
FDA Approved ADC: TRASTUZUMAB + DM1
Recent Advances in the Biotechnology Industry
• Monoclonal Antibodies • Fully humanized products • Exploitation of antibody fragments with favorable
characteristics • Novel scaffolds introduced • Glyco-engineering of antibodies and fusion proteins • First antibody-drug conjugates approved
49
Acknowledgements
Academic/Industry Colleagues: Dr. Marcia Federici Dr. Krish Venkat
Former Graduate Student: Dr. Greg Hamilton
Executive Administrative Assistant: Ms. Susan Mocko
50
Muito Obrigado!
Perguntas?
Antonio Moreira, Ph.D. Vice Provost for Academic Affairs
University of Maryland Baltimore County 1000 Hilltop Circle
Administration Building, Room 1001 Baltimore, MD 21250
Tel: (001) 410-455-6576 Fax: (001) 410-455-1107
Mobile: (001) 443-254-3696 Email: [email protected]
51